Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

64Cu PD 32766

Next Previous
Drug Profile

64Cu PD 32766

Alternative Names: 64Cu-PD-32766

Latest Information Update: 08 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PeptiDream
  • Class Antineoplastics; Peptide diagnostics; Radiopharmaceuticals
  • Mechanism of Action Carbonic anhydrase IX modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase 0 Renal cell carcinoma

Most Recent Events

  • 22 Dec 2025 The US FDA granted the Investigational New Drug clearance for the Phase I clinical trials for Renal cell carcinoma for 225Ac-PD-32766
  • 22 Dec 2025 PeptiDream plans to initiate a phase I trial for Renal cell carcinoma in the US
  • 28 Mar 2025 Efficacy, adverse events and pharmacokinetics data from a phase 0 trial in Renal cell carcinoma released by PeptiDream

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top